Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 9, 2001, Pages 2616-2622

  Lindsten, K ^a   Uhlikova T ^a   Konvalinka, J ^a   Massuci, M G ^a   Dantuma, N P ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; DRUG SCREENING; ENZYME ACTIVITY; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL;

CATALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FLUORESCENCE; GREEN FLUORESCENT PROTEINS; HELA CELLS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; LUMINESCENT PROTEINS; RECOMBINANT FUSION PROTEINS; TITRIMETRY; TRANSFECTION;

EID: 0034869511     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.9.2616-2622.2001     Document Type: Article

References (30)

1. β-galactosidase containing a human immunodeficiency virus protease cleavage site is cleaved and inactivated by human immunodeficiency virus protease
2. Isolation of mutants of human immunodeficiency virus protease based on the toxicity of the enzyme in Escherichia coli
3. Colorimetric assay of HIV-1 proteinase suitable for high-capacity screening
4. Novel bacteriological assay for detection of potential antiviral agents
5. Covalent modification of the active site threonine of proteasomal β subunits and the Escherichia coli homolog HsIV by a new class of inhibitors
6. The structure and function of the aspartic proteinases
7. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections
8. Bioluminescence detection of proteolytic bond cleavage by using recombinant aequorin
9. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase
10. Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor
11. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments
12. Configurations of diastereomeric hydroxyethylene isosteres strongly affect biological activities of a series of specific inhibitors of human-immunodeficiency-virus proteinase
13. Conversion of thymidylate synthase into an HIV protease substrate
14. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer
15. Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells
16. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
17. Inactivation of a yeast transactivator by the fused HIV-1 proteinase: A simple assay for inhibitors of the viral enzyme activity
18. Homologous recombination for rapid phenotyping of HIV
19. Processing of the precursor of NF-κB by the HIV-1 protease during acute infection
20. Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein
21. A genetic screen for the isolation and characterization of site-specific proteases
22. Cleavage of vimentin by different retroviral proteases
23. A microtiter colorimetric assay for the HIV-1 protease
24. A heterologous substrate assay for the HIV-1 protease engineered in Escherichia coli
25. Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2
26. Targeting the HIV-protease in AIDS therapy: A current clinical perspective
27. The green fluorescent protein
28. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: A pharmacokinetic pilot study
29. Proteolytic processing and particle maturation
30. Proteolytic cleavage of microtubule-associated proteins by retroviral proteinases